在其他近期新闻中，Acumen Pharmaceuticals公布了2024财年第三季度财务报告和发展里程碑。公司报告称，其针对早期阿尔茨海默病的主要药物候选sabirnetug的II期ALTITUDE-AD研究取得重大进展。尽管本季度净亏损2980万美元，Acumen的财务状况仍然稳健，拥有2.59亿美元的现金和证券。研发费用为2720万美元。

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L.

在动荡的市场环境中，Acumen Pharmaceuticals Inc. (ABOS)股票已触及52周低点，跌至2.08美元。该公司市值为1.27亿美元，最新价格水平反映出公司面临重大下滑，年初至今已下跌43.5%。根据 InvestingPro ...

Find the latest Acumen Pharmaceuticals, Inc. ABOS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Acumen Pharmaceuticals, Inc. NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic ...

This page features the latest news about the Acumen Pharmaceuticals stock. BTIG maintains Buy rating on Acumen stock amid trial progress BTIG has reaffirmed its Buy rating and $11.00 price target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.